The aim of this study is to evaluate the outcomes and tolerance of immune checkpoint
inhibitors (ICIs) for patients with recurrent chordoma. We reviewed the records of 17 patients …

Chordoma is a rare and aggressive bone tumor. An accurate investigation of tumor
heterogeneity is necessary for the development of effective therapeutic strategies. This study …

Chordoma is a notochord-derived primary tumor of the skull base and vertebral column
known to affect 0.08 to 0.5 per 100,000 persons worldwide. Patients commonly present with …

Background Chordomas are rare tumors arising from the skull base and spine, with
approximately 20 pediatric chordoma cases in the Unitedn States per year. The natural …

Chordoma is a rare bone malignancy with a high rate of local recurrence and distant
metastasis. Although DEP domain-containing protein 1B (DEPDC1B) is implicated in a …

Objectives SWI/SNF‐related matrix‐associated actin‐dependent regulator of chromatin
subfamily B member 1 (SMARCB1) loss is associated with a poor prognosis in chordoma …

Brachyury is an oncogenic transcription factor whose overexpression drives chordoma
growth. The downmodulation of brachyury in chordoma cells has demonstrated therapeutic …

Brain tumours have unresolved challenges that include delay prognosis and lower patient
survival rate. The increased understanding of the molecular pathways underlying cancer …

Background: Chordoma is a type of mesenchymal malignancy with a high recurrence rate
and poor prognosis. Due to its rarity, the tumorigenic mechanism and optimal therapeutic …

Background/Aim: Sacral chordoma is a rare primary bone neoplasm associated with high
morbidity. The aim of this study is to identify demographic and clinicopathological …